1 / 1

Chimiothérapie dose-dense : étude TACT-2 Analyse univariée de la survie sans rechute

Chimiothérapie dose-dense : étude TACT-2 Analyse univariée de la survie sans rechute. 100. aE (271 événements). 80. E (290 événements). Taux à 3 ans (IC 95 ) : E : 90,9 % (89,6-92,0) aE : 91,0 % (89,7-92,2). 60. Taux à 5 ans (IC 95 ) : E : 85,2 % (83,4-86,8) aE : 88,4 % (84,7-87,9).

otis
Download Presentation

Chimiothérapie dose-dense : étude TACT-2 Analyse univariée de la survie sans rechute

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Chimiothérapie dose-dense : étude TACT-2 Analyse univariée de la survie sans rechute 100 aE (271 événements) 80 E (290 événements) Taux à 3 ans (IC95) : E : 90,9 % (89,6-92,0) aE : 91,0 % (89,7-92,2) 60 Taux à 5 ans (IC95) : E : 85,2 % (83,4-86,8) aE : 88,4 % (84,7-87,9) Survie sans rechute (%) 40 HR non ajusté = 0,96 ; IC95 : 0,81 - 1,13 Logrank p = 0,60 20 0 0 1 2 3 4 5 Temps depuis la randomisation (années) Patientes à risque (n) E : 0/2 221 40/2 155 75/2 070 85/1 875 49/1 311 32+9/554 D’après Cameron D et al., abstr. S3-3 actualisé

More Related